Injection sclerotherapy for varicose veins

Cochrane Database of Systematic Reviews

Volumn 2021, Issue 12, 2021, Pages

  de Ávila Oliveira, Ricardo ^a   Riera, Rachel ^b   Vasconcelos, Vladimir ^c   Baptista Silva, Jose CC ^c  

^a FEDERAL UNIVERSITY OF UBERLÂNDIA   (Brazil)

^b Cochrane ^*  (Brazil)

^c FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

CLINICAL EFFECTIVENESS; HUMAN; PATIENT SAFETY; REVIEW; RISK ASSESSMENT; SCLEROTHERAPY; SYSTEMATIC REVIEW; TREATMENT OUTCOME; VARICOSIS; ADVERSE EVENT; VEIN; VEIN INSUFFICIENCY;

HUMANS; SCLEROTHERAPY; VARICOSE ULCER; VARICOSE VEINS; VEINS; VENOUS INSUFFICIENCY;

EID: 85120955635     PISSN: 14651858     EISSN: None     Source Type: Journal    
DOI: 10.1002/14651858.CD001732.pub3     Document Type: Review

References (116)

1. Abramowitz I. The treatment of varicose veins in pregnancy by empty vein compressive sclerotherapy. South African Medical Journal 1973;47(14):607-10. x-wiley/crsRef/2746033
2. Alos J, Carreno P, Lopez JA, Estadella B, Serra-Prat M, Marinel-Lo J. Efficacy and safety of sclerotherapy using polidocanol foam: a controlled clinical trial. European Journal of Vascular and Endovascular Surgery 2006;31(1):101-7. x-wiley/crsRef/19247415
3. Belcaro G, Cesarone M, Di Renzo A, Brandolini R, Coen L, Acerbi G, et al. Treatments for varicose veins: surgery, sclerotherapy, foam sclerotherapy and combined (surgery + sclerotherapy) options. A 10-year, prospective, randomised, controlled, follow-up study. The VEDICO* trial and EST (European Sclerotherapy Trial). Angeiologie 2003;55(1):29-36. x-wiley/crsRef/2746039
4. Belcaro G, Cesarone MR, Di Renzo A, Brandolini R, Coen L, Acerbi G, et al. Foam-sclerotherapy, surgery, sclerotherapy and combined treatment for varicose veins: a 10-year prospective, randomised, controlled trial (VEDICO Trial). Angiology 2003;54(3):307-15. x-wiley/crsRef/2746040
5. Blaise S, Bosson JL, Diamand JM. Ultrasound-guided sclerotherapy of the great saphenous vein with 1% vs. 3% polidocanol foam: a multicentre double-blind randomised trial with 3-year follow-up. European Journal of Vascular and Endovascular Surgery 2010;39(6):779-86. x-wiley/crsRef/19247417
6. NCT00348764. ESGVS: sclerotherapy with lauromacrogol. clinicaltrials.gov/ct2/show/NCT00348764 (first received 6 July 2006). x-wiley/crsRef/19247418
7. Ceulen RP, Bullens-Goessens YI, Pi-Van De Venne SJ, Nelemans PJ, Veraart JC, Sommer A. Outcomes and side effects of duplex-guided sclerotherapy in the treatment of great saphenous veins with 1% versus 3% polidocanol foam: results of a randomized controlled trial with 1-year follow-up. Dermatologic Surgery 2007;33(3):276-81. x-wiley/crsRef/19247420
8. Chleir F, Cornu-Thenard A, Sadoun S, Schadeck M, Van Cleef JF. Echosclerosis of the internal saphenous vein: single dose versus fractionated dose preliminary results of the Afcarp study [Echosclerose del la saphene l'interne: dose unique versus dose fractionne. Resultats preliminaries de l'etude Afcarp]. Phlébologie 1997;50(2):275-80. x-wiley/crsRef/19247422
9. Demagny A. Comparative study into the efficacy of a sclerosant product in the form of liquid or foam in echo-guided sclerosis of the arches of the long and short saphenous veins. Phlébologie 2002;55:133-7. x-wiley/crsRef/19247424
10. Gibson K, Kabnick L, Morrison N, Munavalli G, Regan JD. A multicenter, randomized, placebo-controlled study to evaluate the efficacy and safety of varithena (Polidocanol endovenous microfoam 1%) for symptomatic, visible varicose veins with saphenofemoral junction incompetence. Phlebology 2017;32(3):185-93. x-wiley/crsRef/19247426
11. Gibson K, Wright D, Rush J, Suplick G, Evans E. Validating VeinesQOL/SYM: measuring changes following endovenous microfoam ablation of the great saphenous vein. Phlebology 2010;25:308-9. x-wiley/crsRef/19247427
12. NCT00758420. Randomized, single blind, placebo controlled, to evaluate efficacy and safety of polidocanol endovenous microfoam for treatment of symptomatic, visible varicose veins with SFJ incompetence (pilot). clinicaltrials.gov/ct2/show/NCT00758420 (first received 25 September 2008). x-wiley/crsRef/19247428
13. Goldman MP. Treatment of varicose and telangiectatic leg veins: double-blind prospective comparative trial between aethoxysklerol and sotradecol. Dermatologic Surgery 2002;28(1):52-5. x-wiley/crsRef/2746046
14. Hamel-Desnos C, Allaert FA, Benigni JP, Boitelle G, Chleir F, Ouvry P, et al. Study 3/1. Polidocanol foam 3% versus 1% in the great saphenous vein: early results [Etdue 3/1. Mousse de polidocanol 3% versus 1% dans las grande veine saphene: premiers resultats]. Phlébologie 2005;58(2):165-73. x-wiley/crsRef/19247430
15. Hamel-Desnos C, Ouvry P, Benigni J-P, Boitelle G, Schadeck M, Desnos P, et al. Comparison of 1% and 3% polidocanol foam in ultrasound guided sclerotherapy of the great saphenous vein: a randomised, double-blind trial with 2 year-follow-up. "The 3/1 Study". European Journal of Vascular and Endovascular Surgery 2007;34(6):723-9. x-wiley/crsRef/19247431
16. Hamel-Desnos C, Ouvry P, Desnos P, Allaert FA. 3% versus 1% polidocanol foam in sclerotherapy of the great saphenous vein: randomised double-blind controlled trial with a 2-year follow-up. Study 3/1. Phlébologie 2008;61(1):103-9. x-wiley/crsRef/19247432
17. Kahle B, Leng K, Bolz S. Efficacy of sclerotherapy in varicose veins: a blinded, placebo-controlled study. In: UIP World Congress Chapter Meeting (www.phlebology.org/AbstractUIP.htm#114); 2003. San Diego, 2003. x-wiley/crsRef/19247434
18. Kahle B, Leng K. Efficacy of sclerotherapy in varicose veins - prospective, blinded, placebo-controlled study. Dermatologic Surgery 2004;30(5):723-8. x-wiley/crsRef/19247435
19. King JT, O'Byrne M, Vasquez M, Wright D, VANISH-1 investigator group. Treatment of truncal incompetence and varicose veins with a single administration of a new polidocanol endovenous microfoam preparation improves symptoms and appearance. European Journal of Vascular and Endovascular Surgery 2015;50(6):784-93. x-wiley/crsRef/19247437 [DOI: 10.1016/j.ejvs.2015.06.111]
20. NCT01072877. Efficacy and safety study of VarisolveT polidocanol endovenous microfoam (PEM) for the treatment of saphenofemoral junction (SFJ) incompetence (VANISH-1). clinicaltrials.gov/ct2/show/NCT01072877 (first received 22 February 2010). x-wiley/crsRef/19247438
21. Martimbeau PR. A randomized clinical trial comparing the sclerosing and side effects of foam vs. liquid formula for sclerotherapy of primary varicose veins. In: UIP World Congress Chapter Meeting (www.phlebology.org/AbstractUIP.htm#144); 2003. San Diego, 2003. x-wiley/crsRef/19247440
22. Martimbeau PR. Perfluoropropane-filled albumin microspheres of sodium tetradecylsulphate versus air-filled sodium tetradecylsulphate for foam sclerotherapy of greater saphenous vein incompetence. In: UIP World Congress Chapter Meeting (www.phlebology.org/AbstractUIP.htm#145); 2003. San Diego, 2003. x-wiley/crsRef/2746113
23. Hamel-Desnos C, Desnos P, Ouvry P. New therapeutic methods in the management of varicose disease: echo-sclerotherapy and foam [Nouveautes therapeutiiques dans la prise en charge de la maladie variqueuse: echo-sclerotherapie et mousse]. Phlébologie 2003;56(1):41-8. x-wiley/crsRef/19247442
24. Hamel-Desnos C, Desnos P, Wollmann JC, Ouvry P, Mako S, Allaert FA. Evaluation of the efficacy of polidocanol in the form of foam compared with liquid form in sclerotherapy of the greater saphenous vein: initial results. Dermatologic Surgery 2003;29(12):1170-5. x-wiley/crsRef/19247443
25. Hamel-Desnos C, Ouvry P, Desnos P, Mako S. Evaluation of the efficacy of polidocanol in the form of foam versus liquid form in sclerotherapy of the long saphenous vein. In: 16th Annual Congress of the American College of Phlebology; 7-10 Nov 2002; Fort Lauderdale, Florida. phlebology.org/AbstractsFTL.htm#19. 2002. x-wiley/crsRef/19247444
26. Ouvry P, Allaert FA, Desnos P, Hamel-Desnos C. Efficacy of polidocanol foam versus liquid in sclerotherapy of the great saphenous vein: a multicentre randomised controlled trial with a 2-year follow-up. European Journal of Vascular and Endovascular Surgery 2008;36(3):366-70. x-wiley/crsRef/19247445
27. Rabe E, Otto J, Schliephake D, Pannier F. Efficacy and safety of great saphenous vein sclerotherapy using standardised polidocanol foam (ESAF): a randomised controlled multicentre clinical trial. European Journal of Vascular and Endovascular Surgery 2008;35(2):238-45. x-wiley/crsRef/19247447
28. Ragg JC. Foam sclerotherapy of saphenous veins comparing the effect of injection via needles and catheters of different size. In: Scientific Programme and Book of Abstracts; 16th Meeting of the European Venous Forum; 2015 Jul 2-4; St Petersburg, Russia. 2015:57. x-wiley/crsRef/19247449
29. Rao J, Wildemore JK, Goldman MP. Double-blind prospective comparative trial between foamed and liquid polidocanol and sodium tetradecyl sulfate in the treatment of varicose and telangiectatic leg veins. Dermatologic Surgery 2005;31(6):631-5. x-wiley/crsRef/19247451
30. NCT02753270. Catheter-directed foam sclerotherapy with tumescence. clinicaltrials.gov/ct2/show/NCT02753270 (first received 27 April 2016). x-wiley/crsRef/19247453
31. Santos JB, Junior WC, Porta RMP, Puggina J, Silva DFT, Puch-Leão P, et al. Catheter-directed foam sclerotherapy with tumescence of the great saphenous vein versus ultrasound-guided foam sclerotherapy: a randomized controlled trial. Phlebology 2019;35(2):84-91. x-wiley/crsRef/19247454 [DOI: 10.1177/0268355519850651]
32. Schadeck M. Aetoxisclerol 4% in the treatment of the saphenous veins. In: Negus D, Jantet G, Coleridge-Smith P, editors(s). Phlebology. Vol. 1. Springer Verlag Inc, 1995:620. x-wiley/crsRef/2746064 [ISBN: 3540199993]
33. NCT01231373. Polidocanol endovenous microfoam (PEM) versus vehicle for the treatment of saphenofemoral junction (SFJ) incompetence (VANISH-2). clinicaltrials.gov/ct2/show/NCT01231373 (first received 1 November 2010). x-wiley/crsRef/19247456
34. Todd KL, Wright DI. Durability of treatment effect with polidocanol endovenous microfoam on varicose vein symptoms and appearance (VANISH-2). Journal of Vascular Surgery 2015;3(3):258. x-wiley/crsRef/19247457
35. Todd KL, Wright DI. The VANISH-2 study: a randomized, blinded, multicenter study to evaluate the efficacy and safety of polidocanol endovenous microfoam 0.5% and 1.0% compared with placebo for the treatment of saphenofemoral junction incompetence. Phlebology 2014;29(9):608-18. x-wiley/crsRef/19247458 [DOI: 10.1177/0268355513497709]
36. Ukritmanoroat T. Comparison of efficacy and safety between foam sclerotherapy and conventional sclerotherapy: a controlled clinical trial. Journal of the Medical Association of Thailand 2011;94(Suppl 2):S35-40. x-wiley/crsRef/19247460
37. Wright D, Gobin JP, Bradbury AW, Coleridge-Smith P, Spoelstra H, Berridge D, et al. Varisolve polidocanol microfoam compared with surgery or sclerotherapy in the management of varicose veins in the presence of trunk vein incompetence: European randomized controlled trial. Phlebology 2006;21(4):180-90. x-wiley/crsRef/19247462
38. Wright D. European randomized controlled trial of Varisolve PD microfoam compared with alternative therapy in management of moderate to severe varicose veins: preliminary results. In: UIP World Congress Chapter Meeting; 2003. San Diego, 2003. x-wiley/crsRef/19247463
39. Yamaki T, Nozaki M, Sakurai H, Takeuchi M, Soejima K, Kono T. Multiple small-dose injections can reduce the passage of sclerosant foam into deep veins during foam sclerotherapy for varicose veins. European Journal of Vascular and Endovascular Surgery 2009;37(3):343-8. x-wiley/crsRef/19247465
40. Yamaki T, Hamahata A, Soejima K, Kono T, Nozaki M, Sakurai H. Prospective randomised comparative study of visual foam sclerotherapy alone or in combination with ultrasound-guided foam sclerotherapy for treatment of superficial venous insufficiency: preliminary report. European Journal of Vascular and Endovascular Surgery 2012;43(3):343-7. x-wiley/crsRef/19247467
41. Zeh RG. Expanding sclerosing properties of polidocanol foam with Gelofusine. In: UIP World Congress Chapter Meeting (www.phlebology.org/AbstractUIP.htm#79); 2003. San Diego, 2003. x-wiley/crsRef/2746131
42. Zhang J, Schliephake D, Malouf M, Otto J, Jing Z, Gu Y. Polidocanol/lauromacrogol 400 vs. placebo for sclerotherapy of C1 and C2 non-saphenous trunk varicose veins: a double-blind, randomized, controlled, multicenter clinical trial (Esachina study) performed in the P.R. of China. In: XVI World Congress of the Union Internationale de Phlebologie Abstract Book. 2009:54. x-wiley/crsRef/19247469
43. Zhang WG, Yan RH, Zong HM, Wang QC, Chen DQ, Xu YP. Foam sclerotherapy of lauromacrogol for the treatment of lower extremity varicose veins: comparison study of two different injection ways. Journal of Interventional Radiology 2014;23(5):392-6. x-wiley/crsRef/19247471
44. Ariyoshi H, Kambayashi J, Tominaga S, Hatanaka T. The possible risk of lower-limb sclerotherapy causing an extended hypercoagulable state. Surgery Today 1996;26(5):323-7. x-wiley/crsRef/19247473
45. Biemans AAM, Kockaert M, Akkersdijk GP, Van den Bos RR, De Maeseneer MGR, Cuypers P, et al. Comparing endovenous laser ablation, foam sclerotherapy, and conventional surgery for great saphenous varicose veins. Journal of Vascular Surgery 2013;58(3):727-34. x-wiley/crsRef/19247475
46. Biemans AAM, Kockaert M, Van Den Bos RR, Cuypers P, Neumann HAM, Nijsten TEC. A randomized comparative study of the three most commonly performed treatments for varicose veins, results after one year. Nederlands Tijdschrift voor Dermatologie en Venereologie 2012;22(2):78-84. x-wiley/crsRef/19247476
47. Van der Velden SK, Biemans AA, De Maeseneer MG, Kockaert MA, Cuypers PW, Hollestein LM, et al. Five-year results of a randomized clinical trial of conventional surgery, endovenous laser ablation and ultrasound-guided foam sclerotherapy in patients with great saphenous varicose veins. British Journal of Surgery 2015;102(10):1184-94. x-wiley/crsRef/19247477
48. Brittenden J, Cotton SC, Elders A, Ramsay CR, Norrie J, Burr J, et al. A randomized trial comparing treatments for varicose veins (CLASS). New England Journal of Medicine 2014;371:1218-27. x-wiley/crsRef/19247479 [DOI: 10.1056/NEJMoa1400781]
49. Brittenden J, Cotton SC, Elders A, Tassie E, Scotland G, Ramsay CR, et al. Clinical effectiveness and cost-effectiveness of foam sclerotherapy, endovenous laser ablation and surgery for varicose veins: results from the Comparison of LAser, Surgery and foam Sclerotherapy (CLASS) randomised controlled trial. Health Technology Assessment 2015;19(27):1-342. x-wiley/crsRef/19247480
50. ISRCTN51995477. Randomised controlled trial comparing foam sclerotherapy, alone or in combination with endovenous laser therapy, with conventional surgery as a treatment for varicose veins. isrctn.com/ISRCTN51995477 (first received 25 February 2008). x-wiley/crsRef/19247481
51. Lancet protocol 09PRT/2275. The CLASS Study: Comparison of LAser, Surgery and foam Sclerotherapy as a treatment for varicose veins (EudraCT 2008-001069-26). thelancet.com/protocol-reviews/09PRT-2275 (accessed 24 September 2020). x-wiley/crsRef/19247482
52. ISRCTN03080206. Endovenous laser therapy (EVLT) versus ultrasound guided foam sclerotherapy (UGFS) for the treatment of varicose veins. isrctn.com/ISRCTN03080206 (first received 21 January 2010). x-wiley/crsRef/19247484
53. Kalodiki E, Azzam M, Schnatterbeck P, Geroulakos G, Lattimer CR. The Discord Outcome Analysis (DOA) as a reporting standard at three months and five years in randomised varicose vein treatment trials. European Journal of Vascular and Endovascular Surgery 2018;57(2):267-74. x-wiley/crsRef/19247485 [DOI: 10.1016/j.ejvs.2018.09.013]
54. Lattimer CR, Azzam M, Kalodiki E, Shawish E, Trueman P, Geroulakos G. Cost and effectiveness of laser with phlebectomies compared with foam sclerotherapy in superficial venous insufficiency. Early results of a randomised controlled trial. European Journal of Vascular and Endovascular Surgery 2012;43:594-600. x-wiley/crsRef/19247486
55. Lattimer CR, Kalodiki E, Azzam M, Geroulakos G. Responsiveness of individual questions from the venous clinical severity score and the Aberdeen varicose vein questionnaire. Phlebology 2014;29:43-51. x-wiley/crsRef/19247487
56. Lattimer CR, Kalodiki E, Azzam M, Makris GC, Somiayajulu S, Geroulakos G. Interim results on abolishing reflux alongside a randomized clinical trial on laser ablation with phlebectomies versus foam sclerotherapy. International Angiology 2013;32(4):394-403. x-wiley/crsRef/19247488
57. Leung CC, Carradice D, Wallace T, Chetter IC. Endovenous laser ablation versus mechanochemical ablation withClariVein(®) in the management of superficial venous insufficiency (LAMA trial): study protocol for a randomised controlled trial. Trials 2016;17(1):421. x-wiley/crsRef/19247490
58. Mishra M, Soni R, Mohil R, Sinha A. Comparative study of outcome of duplex ultrasound-guided,catheter-directed foam sclerotherapy and radio-frequency ablation in the management of great saphenous varicose veins. Indian Journal of Surgery 2016;78(5):375-81. x-wiley/crsRef/19247492
59. NCT02462720 2015. COMFORT: multicenter study to evaluate pain following treatment of varicose vein with Varithena® compared to radiofrequency ablation. clinicaltrials.gov/show/NCT02462720 2015 (first received 4 June 2015). x-wiley/crsRef/19247494
60. Ragg JC. Initial and permanent vein lumen minimization obtained with endovenous occlusion techniques by using hyaluronan solution instead of tumescent fluid. In: Scientific Programme and Book of Abstracts; 16th Meeting of the European Venous Forum; 2015; St Petersburg, Russia. Vol. 58. 2015. x-wiley/crsRef/19247496
61. ISRCTN08060326. Endovenous laser ablation (EVLA), radio frequency (RF), foam sclerotherapy and stripping for treatment of varicose veins. isrctn.com/ISRCTN08060326 (first received 31 July 2009). x-wiley/crsRef/19247498 [DOI: 10.1186/ISRCTN08060326]
62. Lawaetz M, Rasmussen LH, Bjoern L, Blemings A, Eklof B. Randomized trial comparing RF, laser, foam sclerotherapy and stripping in varicose veins. Phlebology 2010;25:307. x-wiley/crsRef/19247499
63. Lawaetz M, Serup J, Lawaetz B, Bjoern L, Blemings A, Eklof B, et al. Comparison of endovenous radiofrequency ablation, laser ablation, foam sclerotherapy and surgical stripping for great saphenous varicose veins. Extended 5-year follow-up of a RCT. Phlebology 2017;32(2):13-4. x-wiley/crsRef/19247500
64. Rasmussen L, Lawaetz M, Serup J, Bjoern L, Vennits B, Blemings A, et al. Randomized clinical trial comparing endovenous laser ablation, radiofrequency ablation, foam sclerotherapy, and surgical stripping for great saphenous varicose veins with 3-year follow-up. Journal of Vascular Surgery 2013;1(4):349-56. x-wiley/crsRef/19247501
65. Rasmussen LH, Lawaetz M, Bjoern L, Vennits B, Blemings A, Eklof B. Randomized clinical trial comparing endovenous laser ablation, radiofrequency ablation, foam sclerotherapy and surgical stripping for great saphenous varicose veins. British Journal of Surgery 2011;98(8):1079-87. x-wiley/crsRef/19247502
66. Theivacumar NS, Dellagrammaticas D, Mavor AI, Gough MJ. Endovenous laser ablation: does standard above-knee great saphenous vein ablation provide optimum results in patients with both above-and below-knee reflux? A randomized controlled trial. Journal of Vascular Surgery 2008;48(1):173-8. x-wiley/crsRef/19247504
67. Theivacumar SN, Dellagrammaticas D, Darwood RJ, Mavor AI, Gough MJ. Endovenous laser ablation (EVLA): is standard above-knee great saphenous vein (AK-GSV) ablation sufficient? A randomised controlled trial. Vascular Society of Great Britain & Ireland Yearbook 2007;71. x-wiley/crsRef/19247505
68. Vahaaho S, Alback A, Halmesmki K, Mahmoud O, Venermo M. RCT comparing the long-term results of UGFS, EVLA and open surgery in the treatment of GSV reflux. In: XXIX Annual Meeting European Society for Vascular Surgery; 2015. 2015. x-wiley/crsRef/19247507
69. NCT01298908. Comparison of treatments in venous insufficiency. clinicaltrials.gov/ct2/show/study/NCT01298908 (first received 18 February 2011). x-wiley/crsRef/19457283
70. Venermo M, Saarinen J, Eskelinen E, Vahaaho S, Saarinen E, Railo M, Finnish Venous Study Collaborators. Randomized clinical trial comparing surgery, endovenous laser ablation and ultrasound-guided foam sclerotherapy for the treatment of great saphenous varicose veins. British Journal of Surgery 2016;103(11):1438-44. x-wiley/crsRef/19457284
71. Venermo M. A randomised trial of three VV treatment strategies. ESVS 18-21 September 2013, Budapest, Hungary 2013. x-wiley/crsRef/19457285
72. Zafarghandi MR, Farsavian H, Davoudi M, Farsavian AA. Outcome of ultrasonography-guided foam sclerotherapy versus stab avulsion ambulatory phlebectomy in the treatment of varicosis in small veins of the leg: a single blinded randomized clinical triaI. Iranian Journal of Radiology 2017;14(3):e21742. x-wiley/crsRef/19247513
73. Labas P, Ohrádka B, Cambal M, Ringelband R. The results of compression sclerotherapy. Comparative study of two techniques and two sclerosants. Phlebologie 2000;29:137-41. x-wiley/crsRef/19247514
74. Labas P, Ohradka B, Cambal M, Reis R, Fillo J. Long term results of compression sclerotherapy. Bratislavske Lekarske Listy 2003;104(2):78-81. x-wiley/crsRef/2746054
75. Satokawa H, Hoshino S, Sakaguchi S, Yamada C. The Japanese polidocanol (aethoxysclerol) clinical trial. Abstracts from the UIP World Congress Chapter Meeting 2003. x-wiley/crsRef/19247516
76. Schadeck M, Allaert FA. Post sclerosis recurrences of the great saphenous vein. In: Negus D, Jantet G, Coleridge-Smith PD, editors(s). Phlebology '95. Vol. 1. Springer, 1995:614. x-wiley/crsRef/2746123
77. Anonymous. Sclerotherapy to the long saphenous vein-a less invasive alternative. slctr.lk/trials/slctr-2008-014 (first received 18 July 2008). x-wiley/crsRef/19247518 [SLCTR/2008/014]
78. Varnagy R, Malave G, Taborda J, Gabay N. Clinical trial of a new experimental sclerosant product. Current Therapeutic Research, Clinical and Experimental 1985;38:960-5. x-wiley/crsRef/19247520
79. Allan PL, Bradbury AW, Evans CJ, Lee AJ, Ruckley CV, Fowkes FG. Patterns of reflux and severity of varicose veins in the general population - Edinburgh Vein Study. European Journal of Vascular and Endovascular Surgery 2000;20(5):470-7.
80. Bradbury A, Evans C, Allan P, Lee A, Ruckley CV, Fowkes FG. What are the symptoms of varicose veins? Edinburgh vein study cross sectional population survey. BMJ 1999;318(7180):353-6.
81. Carroll C, Hummel S, Leaviss J, Ren S, Stevens JW, Everson-Hock E, et al. Clinical effectiveness and cost-effectiveness of minimally invasive techniques to manage varicose veins: a systematic review and economic evaluation. Health Technology Assessment 2013;17(48):1–141. [DOI: 10.3310/hta17480]
82. Davies AH. The seriousness of chronic venous disease: a review of real-world evidence. Advances in Therapy 2019;36 (Suppl 1):5-12. [DOI: 10.1007/s12325-019-0881-7]
83. Dechartres A, Trinquart L, Boutron I, Ravaud P. Influence of trial sample size on treatment effect estimates: meta-epidemiological study. BMJ 2013;346:f2304.
84. Deeks JJ, Higgins JP, Altman DG editor(s). Chapter 9: Analysing data and undertaking meta-analyses. In: Higgins JP, Churchill R, Chandler J, Cumpston MS, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.2.0 (updated June 2017). The Cochrane Collaboration. Available from training.cochrane.org/handbook/archive/v5.2.
85. Eklöf B, Rutherford RB, Bergan JJ, Carpentier PH, Peter Gloviczki P, Kistner RL, et al. Revision of the CEAP classification for chronic venous disorders: consensus statement. Journal of Vascular Surgery 2004;40:1248-52. [DOI: 10.1016/j.jvs.2004.09.027]
86. McMaster University (developed by Evidence Prime, Inc.). GRADEpro GDT. Version (accessed 14 January 2019). Hamilton, ON: McMaster University (developed by Evidence Prime, Inc.)., 2015. Available at gradepro.org.
87. Hamdan A. Management of varicose veins and venous insufficiency. JAMA 2012;308(24):2612-21. [DOI: 10.1001/jama.2012.111352]
88. Hammel-Desnos C, Allaert FA. Liquid versus foam sclerotherapy. Phlebology 2009;24:240-246. [DOI: 10.1258/phleb.2009.009047]
89. Higgins JP, Green S, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.2.0 (updated March 2017). The Cochrane Collaboration, 2017. Available from training.cochrane.org/handbook/archive/v5.2/.
90. Higgins JP, Altman DG, Sterne JA, editor(s). Chapter 8: Assessing risk of bias in included studies. In: Higgins JP, Green S, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.2.0 (updated June 2017). The Cochrane Collaboration, 2017. Available from training.cochrane.org/handbook/archive/v5.2.
91. Higgins JP, Deeks JJ, Altman DG. Chapter 16: Special topics in statistics. In: Higgins JP, Green S, editor(s). Cochrane Handbook for Systematic Review of interventions Version 5.2.0 (updated March 2017), The Cochrane Collaboration, 2017. Available from training.cochrane.org/handbook/archive/v5.2.
92. Jacobs CE, Pinzon MM, Orozco J, Hunt PJ, Hivera A, McCarthy WJ. Deep venous thrombosis after saphenous endovenous radiofrequency ablation: is it predictable? Annals of Vascular Surgery 2014;28(3):679-85. [DOI: 10.1016/j.avsg.2013.08.012]
93. Kearon C, Akl EA, Ornelas J, Blaivas A, Jimenez D, Bounameaux H, et al. Antithrombotic therapy for VTE disease: CHEST guideline and expert panel report. Chest 2016;149(2):315-52.
94. Kingsley J, King T, Orfe E, Wright D. Capturing the visual impact of varicose veins. Journal of Vascular Surgery 2012;55(6 suppl):62S. [DOI: 10.1016/j.jvs.2012.03.163]
95. Labropoulos N, Dells KT, Nicolaides AN. Venous reflux in symptom-flee vascular surgeons. Journal of Vascular Surgery 1995;22(2):150-4.
96. Launois R. Health-related quality-of-life scales specific for chronic venous disorders of the lower limbs. Journal of Vascular Surgery 2015;3:219-27. [DOI: 10.1016/j.jvsv.2014.08.005]
97. Lefebvre C, Manheimer E, Glanville J. Chapter 6: Searching for studies. In: Higgins JP, Green S, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration. Available from training.cochrane.org/handbook/archive/v5.1.
98. Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gøtzsche PC, Ioannidis JPA, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration. British Medical Journal 2009;339:b2700.
99. O’Hare JL, Earnshaw JJ. Randomised clinical trial of foam sclerotherapy for patients with a venous leg ulcer. European Journal of Vascular and Endovascular Surgery 2010;39:495-9.
100. Paravastu SC, Horne M, Dodd PD. Endovenous ablation therapy (laser or radiofrequency) or foam sclerotherapy versus conventional surgical repair for short saphenous varicose veins. Cochrane Database of Systematic Reviews 2016, Issue 11. Art. No: CD010878. [DOI: 10.1002/14651858.CD010878.pub2]
101. Piazza G. Varicose veins. Circulation 2014;130:582-7. [DOI: 10.1161/CIRCULATIONAHA.113.008331.]
102. Pollak JS, White Jr RI. Chapter 32: Peripheral vascular malformations. In: Peripheral vascular interventions. Philadelphia: Lippincott Williams & Wilkins, 2008.
103. Rabe E, Pannier F. Sclerotherapy of varicose veins with polidocanol based on the guidelines of the German Society of Phlebology. Dermatologic Surgery 2010;36:968-75.
104. Rabe E, Guex JJ, Puskas A, Scuderi A, Fernandez Quesada F. Epidemiology of chronic venous disorders in geographically diverse populations: results from the Vein Consult Program. International Angiology 2012;31(2):105-15.
105. Rabe E, Breu FX, Cavezzi A, Coleridge Smith P, Frullini A, Gillet JL, et al. European guidelines for sclerotherapy in chronic venous disorders. Phlebology 2014;29(6):338-54. [DOI: 10.1177/0268355513483280]
106. Rathbun S, Norris A, Stoner J. Efficacy and safety of endovenous foam sclerotherapy: meta-analysis for treatment of venous disorders. Phlebology 2012;27:105-17. [DOI: 10.1258/phleb.2011.011111]
107. Nordic Cochrane Centre, The Cochrane Collaboration Review Manager 5 (RevMan 5). Version 5.3. Copenhagen: Nordic Cochrane Centre, The Cochrane Collaboration, 2014.
108. Sarvananthan T, Shepherd AC, Willenberg T, Davies AH. Neurologicalcomplications of sclerotherapy for varicose veins. Journal of Vascular Surgery 2012;55(1):243-51. [DOI: 10.1016/j.jvs.2011.05.093]
109. Schünemann HJ, Oxman AD, Vist GE, Higgins JP, Deeks JJ, Glasziou P, et al. Chapter 12: Interpreting results and drawing conclusions. In: Higgins JPT, Green S (editors), Cochrane Handbook for Systematic Reviews of Interventions Version 5.2.0 (updated June 2017), The Cochrane Collaboration. Available from training.cochrane.org/handbook/archive/v5.2.
110. Smyth RM, Aflaifel N, Bamigboye AA. Interventions for varicose veins and leg oedema in pregnancy. Cochrane Database of Systematic Reviews 2015, Issue 10. Art. No: CD001066. [DOI: 10.1002/14651858.CD001066.pub3]
111. Whiteley MS, Dos Santos SJ, Fernandez-Hart TJ, Lee CTD, Li JM. Media damage following detergent sclerotherapy appears to be secondary to the induction of inflammation and apoptosis: an immunohistochemical study elucidating previous histological observations. European Journal of Vascular and Endovascular Surgery 2016;51:421-8.
112. Willenberg T, Smith PC, Shepherd A, Davies AH. Visual disturbance following sclerotherapy for varicose veins, reticular veins and telangiectasias: a systematic literature review. Phlebology 2013;28(3):123-31. [DOI: 10.1177/0268355513486745]
113. Wu AR, Garry J, Labropoulos N. Incidence of pulmonary embolism in patients with isolated calf deep vein thrombosis. Journal of Vascular Surgery 2017;5(2):274-9.
114. Young GL, Jewell D. Interventions for varicosities and leg oedema in pregnancy. Cochrane Database of Systematic Reviews 1998, Issue 2. Art. No: CD001066. [DOI: 10.1002/14651858.CD001066]
115. Tisi PV, Beverley CA. Injection sclerotherapy for varicose veins. Cochrane Database of Systematic Reviews 2002, Issue 1. Art. No: CD001732. [DOI: 10.1002/14651858.CD001732]
116. Tisi PV, Beverley C, Rees A. Injection sclerotherapy for varicose veins. Cochrane Database of Systematic Reviews 2006, Issue 4. Art. No: CD001732. [DOI: 10.1002/14651858.CD001732.pub2]